Per Artikel

Riset dan Pengabdian Masyarakat Do Research Sosial Service and Innovation

Id	Authors	Author S Id	Title	Year	Source Title	Volume	Issue	Art No	Page Start	Page End	Cited By	Link	Affiliations	Authors With Affiliations	Abstract	Author Keywords	Index Keywords	Publisher	Issn	Pubmed Id	Document Type	Sjr Best Quartile	Sjr	Sjr Rank
Display # Page 76 of 93 Start Prev 71 72 73 74 75 76 77 78 79 80 Next End
5078(5)
No records
541	Fujiwara T., Hoshide S., Tomitani N., Cheng H.-M., Soenarta A.A., Turana Y., Chen C.-H., Minh H.V., Sogunuru G.P., Tay J.C., Wang T.-D., Chia Y.-C., Verma N., Li Y., Wang J.-G., Kario K.	57212076752;6603859769;57189644362;57026688600;6507634613;56083326000;7501963868;57211946145;26428524900;24330212600;7405566618;57204080905;7102496979;55931488300;57211730247;7102633390;	Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in Asia	2021	Journal of Clinical Hypertension	23	3		457	466	4	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101488308&doi=10.1111%2fjch.14218&partnerID=40&md5=d3540818497da0e2ae884c08bf5b5ad6	Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Center for Evidence-Based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Jakarta, Indonesia; Faculty of Medical and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Viet Nam; Department of Cardiology, MIOT International Hospital, Chennai, India; College of Medical Sciences, Kathmandu University, Bharatpur, Nepal; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia; Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Physiology, King George's Medical University, Lucknow, India; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China	Fujiwara, T., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan; Hoshide, S., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan; Tomitani, N., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan; Cheng, H.-M., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan, Center for Evidence-Based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Soenarta, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Jakarta, Indonesia; Turana, Y., Faculty of Medical and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Chen, C.-H., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Minh, H.V., Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Viet Nam; Sogunuru, G.P., Department of Cardiology, MIOT International Hospital, Chennai, India, College of Medical Sciences, Kathmandu University, Bharatpur, Nepal; Tay, J.C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Wang, T.-D., Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Chia, Y.-C., Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia, Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Verma, N., Department of Physiology, King George's Medical University, Lucknow, India; Li, Y., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Wang, J.-G., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan	Nocturnal home blood pressure (BP) monitoring has been used in clinical practice for ~20 years. The authors recently showed that nocturnal systolic BP (SBP) measured by a home BP monitoring (HBPM) device in a Japanese general practice population was a significant predictor of incident cardiovascular disease (CVD) events, independent of office and morning home SBP levels, and that masked nocturnal hypertension obtained by HBPM (defined as nocturnal home BP ≥ 120/70 mmHg and average morning and evening BP < 135/85 mmHg) was associated with an increased risk of CVD events compared with controlled BP (nocturnal home BP < 120/70 mmHg and average morning and evening BP < 135/85 mmHg). This evidence revealed that (a) it is feasible to use a nocturnal HBPM device for monitoring nocturnal BP levels, and (b) such a device may offer an alternative to ambulatory BP monitoring, which has been the gold standard for the measurement of nocturnal BP. However, many unresolved clinical problems remain, such as the measurement schedule and conditions for the use of nocturnal HBPM. Further investigation of the measurement of nocturnal BP using an HBPM device and assessments of the prognostic value are thus warranted. Asians are at high risk of developing nocturnal hypertension due to high salt sensitivity and salt intake, and the precise management of their nocturnal BP levels is important. Information and communication technology-based monitoring devices are expected to facilitate the management of nocturnal hypertension in Asian populations. © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC	Asia; blood pressure; blood pressure monitoring; nocturnal home blood pressure; nocturnal hypertension	albumin to creatinine ratio; Asia; blood pressure measurement; blood pressure monitoring; blood pressure regulation; cardiovascular disease; clinical feature; clinical research; diagnostic value; feasibility study; general practice; gold standard; high risk population; human; hypertension; Japanese (people); medical informatics; nocturnal home blood pressure monitoring; nocturnal hypertension; organ injury; pathophysiology; prognosis; Review; salt intake; systolic blood pressure; target organ damage; blood pressure; blood pressure monitoring; hypertension; masked hypertension; Asia; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Masked Hypertension	John Wiley and Sons Inc	15246175	33591641	Review	Q2	909	5078	View
547	Tsoi K., Yiu K., Lee H., Cheng H.-M., Wang T.-D., Tay J.-C., Teo B.W., Turana Y., Soenarta A.A., Sogunuru G.P., Siddique S., Chia Y.-C., Shin J., Chen C.-H., Wang J.-G., Kario K., the HOPE Asia Network	16065259000;24167446900;57271749300;57026688600;7405566618;24330212600;23570166200;56083326000;6507634613;26428524900;57210091066;57204080905;54791393300;7501963868;57211730247;7102633390;	Applications of artificial intelligence for hypertension management	2021	Journal of Clinical Hypertension	23	3		568	574	4	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100377966&doi=10.1111%2fjch.14180&partnerID=40&md5=cdd3526a471a2db59f4ca490ffd9d59b	SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Department of Neurology, School of Medicine and health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Cardiology, MIOT international hospital, Chennai, India; Punjab Medical Center, Lahore, Pakistan; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia; Faculty of Medicine, Department of Primary Care Medicine, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan	Tsoi, K., SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong, JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Yiu, K., SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong; Lee, H., JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Cheng, H.-M., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan, Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Wang, T.-D., Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Tay, J.-C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Teo, B.W., Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Turana, Y., Department of Neurology, School of Medicine and health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia; Soenarta, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sogunuru, G.P., Department of Cardiology, MIOT international hospital, Chennai, India; Siddique, S., Punjab Medical Center, Lahore, Pakistan; Chia, Y.-C., Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia, Faculty of Medicine, Department of Primary Care Medicine, University of Malaya, Kuala Lumpur, Malaysia; Shin, J., Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Chen, C.-H., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Wang, J.-G., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; the HOPE Asia Network	The prevalence of hypertension is increasing along with an aging population, causing millions of premature deaths annually worldwide. Low awareness of blood pressure (BP) elevation and suboptimal hypertension diagnosis serve as the major hurdles in effective hypertension management. The advent of artificial intelligence (AI), however, sheds the light of new strategies for hypertension management, such as remote supports from telemedicine and big data-derived prediction. There is considerable evidence demonstrating the feasibility of AI applications in hypertension management. A foreseeable trend was observed in integrating BP measurements with various wearable sensors and smartphones, so as to permit continuous and convenient monitoring. In the meantime, further investigations are advised to validate the novel prediction and prognostic tools. These revolutionary developments have made a stride toward the future model for digital management of chronic diseases. © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.		antihypertensive agent; antihypertensive therapy; artificial intelligence; blood pressure monitoring; blood pressure regulation; disease burden; feasibility study; health care cost; human; hypertension; incidence; lifestyle modification; mobile application; outcome assessment; prediction; prognosis; Review; telemedicine; trend study; validation process; aged; artificial intelligence; hypertension; telemedicine; Aged; Artificial Intelligence; Humans; Hypertension; Telemedicine	John Wiley and Sons Inc	15246175	33533536	Review	Q2	909	5078	View
551	Turana Y., Tengkawan J., Chia Y.C., Shin J., Chen C.-H., Park S., Tsoi K., Buranakitjaroen P., Soenarta A.A., Siddique S., Cheng H.-M., Tay J.C., Teo B.W., Wang T.-D., Kario K.	56083326000;57201472878;57204080905;54791393300;7501963868;8556278400;16065259000;6603376248;6507634613;57210091066;57026688600;24330212600;23570166200;7405566618;7102633390;	Mental health problems and hypertension in the elderly: Review from the HOPE Asia Network	2021	Journal of Clinical Hypertension	23	3		504	512		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097219445&doi=10.1111%2fjch.14121&partnerID=40&md5=67d4846f474282e2b6bd32d52a692db9	School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia; Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, South Korea; JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; Division of Hypertension, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Jakarta, Indonesia; Punjab Medical Center, Lahore, Pakistan; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Center for Evidence-Based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan	Turana, Y., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Tengkawan, J., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Chia, Y.C., Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia, Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Shin, J., Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Chen, C.-H., Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Park, S., Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, South Korea; Tsoi, K., JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; Buranakitjaroen, P., Division of Hypertension, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Soenarta, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Jakarta, Indonesia; Siddique, S., Punjab Medical Center, Lahore, Pakistan; Cheng, H.-M., Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Center for Evidence-Based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan; Tay, J.C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Teo, B.W., Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Wang, T.-D., Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan	The “triple burden” of aging population, hypertension, and mental health problems making elderly in Asia is more vulnerable. There is evidence of a bidirectional relationship between mental health and hypertension, which results in lower quality of life, lower rate of treatment adherence, and higher mortality among elderly individuals. It is essential to overcome known barriers and care for the elderly with high-risk factors in order to address these burdens. This review revealed that elderly with hypertension were more likely to suffer from depression and anxiety. Therefore, debunking myths, creating awareness regarding mental health, and increasing access to mental health resources through holistic community-based programs would greatly reduce such problems and optimize the chances of success in controlling hypertension-related problems. © 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC	Asia; elderly; hypertension; mental health	antihypertensive agent; aged; anxiety; Asia; cardiovascular disease; cerebrovascular disease; community mental health service; comorbidity; depression; disease association; disease burden; elderly care; health care access; high risk population; human; hypertension; late life depression; life stress; loneliness; medication compliance; mental disease; mental health; motivation; patient compliance; Review; anxiety disorder; hypertension; mental health; quality of life; Aged; Anxiety Disorders; Asia; Humans; Hypertension; Mental Health; Quality of Life	John Wiley and Sons Inc	15246175	33283971	Review	Q2	909	5078	View
552	Chang H.-C., Cheng H.-M., Chen C.-H., Wang T.-D., Soenarta A.A., Turana Y., Teo B.W., Tay J.C., Tsoi K., Wang J.-G., Kario K.	57208131716;57026688600;7501963868;7405566618;6507634613;56083326000;23570166200;24330212600;16065259000;57211730247;7102633390;	Dietary intervention for the management of hypertension in Asia	2021	Journal of Clinical Hypertension	23	3		538	544		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097029615&doi=10.1111%2fjch.14116&partnerID=40&md5=dd0dddd11a11196e4a83b9fd85ea06f2	Department of Medicine, Taipei Veterans General Hospital Su-Ao and Yuan-Shan Branch, Yilan, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Education, Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Division of Cardiology, National Taiwan University Hospital, Taipei, Taiwan; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, the Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan	Chang, H.-C., Department of Medicine, Taipei Veterans General Hospital Su-Ao and Yuan-Shan Branch, Yilan, Taiwan; Cheng, H.-M., Department of Medicine, Taipei Veterans General Hospital Su-Ao and Yuan-Shan Branch, Yilan, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Department of Medical Education, Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Chen, C.-H., Department of Medicine, Taipei Veterans General Hospital Su-Ao and Yuan-Shan Branch, Yilan, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Department of Medical Education, Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Wang, T.-D., Division of Cardiology, National Taiwan University Hospital, Taipei, Taiwan; Soenarta, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Turana, Y., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Teo, B.W., Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Tay, J.C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Tsoi, K., JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Wang, J.-G., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, the Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan	Hypertension is among the leading global risks for premature death. As the risks substantially increase along with the elevated blood pressure, a small reduction of blood pressure could have prevented numerous cardiovascular events in general population. Evidence has shown that dietary intervention is a cost-effective strategy that has been broadly advocated in the published guidelines. However, the implementation could be limited by different food cultures. This review details the mechanisms of each dietary intervention approach, evidence, and the implications in Asian populations, and the perspective of future research. © 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC	dietary intervention; hypertension	aldosterone; calcium; catecholamine; magnesium; potassium; renin; Asia; blood pressure regulation; body weight loss; calcium blood level; caloric restriction; cardiovascular risk factor; cost effectiveness analysis; cultural anthropology; DASH diet; diastolic blood pressure; diet supplementation; diet therapy; dietary pattern; disease association; electrolyte intake; evidence based medicine; fluid retention; food security; human; hyperinsulinemia; hypertension; ideal body weight; insulin resistance; lifestyle modification; magnesium blood level; Mediterranean diet; mortality; obesity; potassium blood level; potassium intake; practice guideline; renin angiotensin aldosterone system; Review; sodium restriction; sodium retention; sodium transport; sodium urine level; systolic blood pressure;	John Wiley and Sons Inc	15246175	33274585	Review	Q2	909	5078	View
553	Turana Y., Tengkawan J., Chia Y.C., Nathaniel M., Wang J.-G., Sukonthasarn A., Chen C.-H., Minh H.V., Buranakitjaroen P., Shin J., Siddique S., Nailes J.M., Park S., Teo B.W., Sison J., Ann Soenarta A., Hoshide S., Tay J.C., Prasad Sogunuru G., Zhang Y., Verma N., Wang T.-D., Kario K., the HOPE Asia Network	56083326000;57201472878;57204080905;57220063330;57211730247;12793132900;7501963868;57211946145;6603376248;54791393300;57210091066;57204676117;8556278400;23570166200;36764809200;56545726300;6603859769;24330212600;57220061819;56183109800;7102496979;7405566618;7102633390;	Hypertension and stroke in Asia: A comprehensive review from HOPE Asia	2021	Journal of Clinical Hypertension	23	3		513	521	5	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096667710&doi=10.1111%2fjch.14099&partnerID=40&md5=85c747eb49b66c56895a7650e9a82984	School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia; Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Medicine, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Cardiology, Hue University Hospital, Hue University, Hue City, Viet Nam; Division of Hypertension, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Punjab Medical Center, Lahore, Pakistan; University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, Philippines; Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, South Korea; Division of Nephrology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore; Division of Nephrology, Department of Medicine, National University Health System, Singapore City, Singapore; Section of Cardiology, Department of Medicine, Medical Center Manila, Manila, Philippines; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; MIOT International Hospital, Chennai, India; College of Medical Sciences, Kathmandu University, Bharatpur, Nepal; Divisions of Hypertension and Heart Failure, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Physiology, King George's Medical University, Lucknow, India; Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan	Turana, Y., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Tengkawan, J., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Chia, Y.C., Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia, Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Nathaniel, M., School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Wang, J.-G., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Sukonthasarn, A., Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Chen, C.-H., Department of Medicine, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Minh, H.V., Department of Cardiology, Hue University Hospital, Hue University, Hue City, Viet Nam; Buranakitjaroen, P., Division of Hypertension, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Shin, J., Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Siddique, S., Punjab Medical Center, Lahore, Pakistan; Nailes, J.M., University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, Philippines; Park, S., Division of Cardiology, Cardiovascular Hospital, Yonsei Health System, Seoul, South Korea; Teo, B.W., Division of Nephrology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore, Division of Nephrology, Department of Medicine, National University Health System, Singapore City, Singapore; Sison, J., Section of Cardiology, Department of Medicine, Medical Center Manila, Manila, Philippines; Ann Soenarta, A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia-National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia; Hoshide, S., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; Tay, J.C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Prasad Sogunuru, G., MIOT International Hospital, Chennai, India, College of Medical Sciences, Kathmandu University, Bharatpur, Nepal; Zhang, Y., Divisions of Hypertension and Heart Failure, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Verma, N., Department of Physiology, King George's Medical University, Lucknow, India; Wang, T.-D., Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; the HOPE Asia Network	Stroke is the primary cause of disability and vascular death worldwide, including Asia. Asian characteristics that differ from the West lead to higher stroke incidence. Stroke epidemiology studies in Asia have shown varying levels of mortality, incidence, prevalence, and burden of disease. Hypertension is the most prevalent risk factor found in Asia. Besides ethnicity that is associated with stroke incidence, both systolic blood pressure, diastolic blood pressure, and blood pressure variability are positively correlated with stroke incidence. Post-stroke cognitive impairment is one of the sequelae that affect one-third of stroke survivors and has become a significant public health concern that is often neglected despite its increasing prevalence. Therefore, it is very important to prevent recurrence by treating stroke optimally and effectively. Increasing awareness and treatment adherence to hypertension, the leading risk factor for stroke, became the main goal in several countries in Asia. © 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.	Asia; hypertension; stroke	Asia; awareness; blood pressure variability; cerebrovascular accident; clinical effectiveness; dementia; diastolic blood pressure; disease burden; global health; human; hypertension; incidence; medication compliance; mortality rate; post stroke dementia; prevalence; recurrent disease; Review; risk factor; systolic blood pressure; blood pressure; cerebrovascular accident; hypertension; Asia; Blood Pressure; Humans; Hypertension; Incidence; Risk Factors; Stroke	John Wiley and Sons Inc	15246175	33190399	Review	Q2	909	5078	View
518(2)
No records
124	Bartlett A.W., Sudjaritruk T., Mohamed T.J., Anugulruengkit S., Kumarasamy N., Phongsamart W., Ly P.S., Truong K.H., Van Nguyen L., Do V.C., Ounchanum P., Puthanakit T., Chokephaibulkit K., Lumbiganon P., Kurniati N., Nik Yusoff N.K., Wati D.K., Sohn A.H., Kariminia A.	56511395900;36538198800;46961185600;57209773680;7003549856;8885235300;9743902800;35811540200;54396225800;56732729400;57200558813;8071686900;7003974471;35564244800;36473260300;6504631866;55816676300;7006405275;6602745222;	Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia	2021	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	73	7		e1919	e1926		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118283335&doi=10.1093%2fcid%2fciaa872&partnerID=40&md5=7af8cf47bd95718a30d3277b5797f9ba	Kirby Institute, University of New South Wales, Sydney, Australia; Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Children's Hospital 1, Ho Chi Minh City, Viet Nam; National Hospital of PediatricsHanoi, Viet Nam; Children's Hospital 2, Ho Chi Minh City, Viet Nam; Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Sanglah Hospital, Udayana UniversityBali, Indonesia; TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand	Bartlett, A.W., Kirby Institute, University of New South Wales, Sydney, Australia; Sudjaritruk, T., Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Mohamed, T.J., Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Anugulruengkit, S., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Phongsamart, W., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Ly, P.S., National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Truong, K.H., Children's Hospital 1, Ho Chi Minh City, Viet Nam; Van Nguyen, L., National Hospital of PediatricsHanoi, Viet Nam; Do, V.C., Children's Hospital 2, Ho Chi Minh City, Viet Nam; Ounchanum, P., Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Puthanakit, T., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chokephaibulkit, K., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Lumbiganon, P., Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Kurniati, N., Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Nik Yusoff, N.K., Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Wati, D.K., Sanglah Hospital, Udayana UniversityBali, Indonesia; Sohn, A.H., TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand; Kariminia, A., Kirby Institute, University of New South Wales, Sydney, Australia	BACKGROUND: Combination antiretroviral therapy (cART) failure is a major threat to human immunodeficiency virus (HIV) programs, with implications for individual- and population-level outcomes. Adolescents with perinatally acquired HIV infection (PHIVA) should be a focus for treatment failure given their poorer outcomes compared to children and adults. METHODS: Data (2014-2018) from a regional cohort of Asian PHIVA who received at least 6 months of continuous cART were analyzed. Treatment failure was defined according to World Health Organization criteria. Descriptive analyses were used to report treatment failure and subsequent management and evaluate postfailure CD4 count and viral load trends. Kaplan-Meier survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTFU) by treatment failure status. RESULTS: A total 3196 PHIVA were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had experienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.78 per 100 person-years. Of the 292 treatment failure events, 31 (10.6%) had a subsequent cART switch within 6 months, which resulted in better immunologic and virologic outcomes compared to those who did not switch cART. The 5-year cumulative incidence of death and LTFU following treatment failure was 18.5% compared to 10.1% without treatment failure. CONCLUSIONS: Improved implementation of virologic monitoring is required to realize the benefits of virologic determination of cART failure. There is a need to address issues related to accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and the role of antiretroviral resistance testing. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.	adolescent; antiretroviral therapy; HIV; treatment failure	anti human immunodeficiency virus agent; adolescent; adult; Asia; CD4 lymphocyte count; child; female; human; Human immunodeficiency virus infection; pregnancy; treatment failure; virus load; Adolescent; Adult; Anti-HIV Agents; Asia; CD4 Lymphocyte Count; Child; Female; HIV Infections; Humans; Pregnancy; Treatment Failure; Viral Load	NLM (Medline)	15376591	32589711	Article	Q1	3440	518	View
173	Forrat R., Dayan G.H., DiazGranados C.A., Bonaparte M., Laot T., Capeding M.R., Sanchez L., Coronel D.L., Reynales H., Chansinghakul D., Hadinegoro S.R.S., Perroud A.P., Frago C., Zambrano B., Machabert T., Wu Y., Luedtke A., Price B., Vigne C., Haney O., Savarino S.J., Bouckenooghe A., Noriega F.	36339272700;6701860993;56721307400;56614799700;24471016000;6602161242;57201082261;56418742600;55343075300;29067671300;56893685800;57198777256;56255310300;7801355579;57201364463;57215829074;54395741500;57002517700;57192890936;57215866119;57220410062;18233281300;7005980306;	Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America	2021	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	73	6		1003	1012	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116958578&doi=10.1093%2fcid%2fciab288&partnerID=40&md5=cceec1a946e6b236b138dcb4bb663855	Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Clinical Sciences Sanofi PasteurPA, United States; Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Clinical Sciences, Sanofi PasteurMexico City, Mexico; Centro de Atencion e Investigación Médica, Bogotá, Colombia; Research & Development, Sanofi PasteurBangkok, Thailand; Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Clinical Sciences, Sanofi Pasteur, Singapore; Clinical Sciences, Sanofi Pasteur, Uruguay; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Global Pharmacovigilance, Sanofi PasteurPA, United States	Forrat, R., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Dayan, G.H., Clinical Sciences Sanofi PasteurPA, United States; DiazGranados, C.A., Clinical Sciences Sanofi PasteurPA, United States; Bonaparte, M., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Laot, T., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Capeding, M.R., Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Sanchez, L., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Coronel, D.L., Clinical Sciences, Sanofi PasteurMexico City, Mexico; Reynales, H., Centro de Atencion e Investigación Médica, Bogotá, Colombia; Chansinghakul, D., Research & Development, Sanofi PasteurBangkok, Thailand; Hadinegoro, S.R.S., Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Perroud, A.P., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Frago, C., Clinical Sciences, Sanofi Pasteur, Singapore; Zambrano, B., Clinical Sciences, Sanofi Pasteur, Uruguay; Machabert, T., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Wu, Y., Clinical Sciences Sanofi PasteurPA, United States; Luedtke, A., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Price, B., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Vigne, C., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Haney, O., Global Pharmacovigilance, Sanofi PasteurPA, United States; Savarino, S.J., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Bouckenooghe, A., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Noriega, F., Clinical Sciences Sanofi PasteurPA, United States	BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.	CYD-TDV; dengue; serostatus; VCD	dengue vaccine; live vaccine; vaccine; virus antibody; Asia; child; controlled study; dengue; Dengue virus; follow up; human; randomized controlled trial; severe dengue; South and Central America; Antibodies, Viral; Asia; Child; Dengue; Dengue Vaccines; Dengue Virus; Follow-Up Studies; Humans; Latin America; Severe Dengue; Vaccines, Attenuated; Vaccines, Combined	NLM (Medline)	15376591	33822015	Article	Q1	3440	518	View
5263(1)
No records
673	Kaaffah S., Soewondo P., Riyadina W., Renaldi F.S., Sauriasari R.	57331465300;23475336100;57208470391;57331465400;16246507200;	Adherence to treatment and glycemic control in patients with type 2 diabetes mellitus: A 4-year follow-up ptm bogor cohort study, indonesia	2021	Patient Preference and Adherence	15			2467	2477		https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118951660&doi=10.2147%2fPPA.S318790&partnerID=40&md5=079f3b92c2c91638e7785757da719eff	Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Division of Endocrinology, Department of Internal Medicine, Dr.Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, Jakarta, Indonesia	Kaaffah, S., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Soewondo, P., Division of Endocrinology, Department of Internal Medicine, Dr.Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Riyadina, W., National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, Jakarta, Indonesia; Renaldi, F.S., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; Sauriasari, R., Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia	Purpose: Large-scale evaluation of the treatment adherence in patients with type 2 diabetes mellitus (DM) in Indonesian is limited. We aim to evaluate the treatment adherence of Indonesian type 2 DM patients using national “big data” and investigate its association with glycemic parameters. Patients and Methods: We analyzed baseline and fourth-year data sets from 2011 to 2018 obtained from the Indonesian Ministry of Health Cohort Study of Non-Communicable Disease Risk Factors in Bogor, West Java (the PTM Bogor Cohort Study). This was a retrospective cohort study in which the sample was divided into two groups. One group adhered to treatment from primary health centers and followed the prescribed medicine/ treatment regimen (treated group), while the other did not follow the treatment (untreated group). We evaluated changes in fasting blood glucose (FBG) and post-prandial blood glucose (PPBG) by controlling for other variables. Results: From 5690 subjects, 593 were type 2 DM diagnosed and 342 were eligible at the baseline. At 4-year observation, 212 eligible patients remained, consisting of 62 subjects who adhered to treatment, and more than double that number who were untreated (150 subjects). More significant decreases in FBG and PPBG were found in the treated group (FBG 80.6%, PPBG 90.3%) than in the untreated group (FBG 42.0%, PPBG 67.3%). The results of the multivariate analysis showed that after 4 years observation, treated patients have reduced FBG 3.304 times more and PPBG 3.064 times more than untreated patients, with control factors such as decrease in LDL levels and use of oral drugs. Conclusion: There were less than half as many treated patients as untreated patients involved in the PTM Bogor Study Group. At the fourth-year follow-up, treated patients experienced three times more significant decreases in FBG and PPBG than those who were untreated, even after being controlled by several confounding factors. Given the importance of these findings, it is suggested that immediate strategic action be taken to improve Indonesian patients’ adherence to treatment. © 2021 Kaaffah et al.	Cohort; Diabetes mellitus; Fasting blood glucose; Post-prandial blood glucose; Treatment adherence	glibenclamide; glimepiride; glucose; insulin; low density lipoprotein; metformin; sulfonylurea; adult; Article; big data; cohort analysis; controlled study; fasting; female; follow up; glucose blood level; glycemic control; human; Indonesia; major clinical study; male; medication compliance; middle aged; non insulin dependent diabetes mellitus; patient compliance; prescription; primary health care; retrospective study	Dove Medical Press Ltd	1177889X		Article	Q1	885	5263	View
5279(1)
No records
110	Abdullah M., Sukartini N., Nursyirwan S.A., Pribadi R.R., Maulahela H., Utari A.P., Muzellina V.N., Wiraatmadja A., Renaldi K.	7103393434;6505680329;57249143800;57194732282;57189612709;57113585900;57223968527;57249709700;57190963547;	Gut Microbiota Profiles in Early-and Late-Onset Colorectal Cancer: A Potential Diagnostic Biomarker in the Future	2021	Digestion	102	6		823	832	1	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114428104&doi=10.1159%2f000516689&partnerID=40&md5=b8c0c7b633dbb180aa40d5f20e5481d7	Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Clinical Pathology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Abdullah, M., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia, Human Cancer Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sukartini, N., Department of Clinical Pathology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Nursyirwan, S.A., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Pribadi, R.R., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Maulahela, H., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Utari, A.P., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Muzellina, V.N., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Wiraatmadja, A., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Renaldi, K., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia	Background: Researchers believe the role of gut microbiota dysbiosis in the raised incidence of early-onset colorectal cancer (EOCRC). The development of EOCRC may be associated with microbiota dysbiosis either dependently or independently (combined with other risk factors). Summary: Recently, the rising of incidence and mortality of EOCRC have been noted. Some researchers are looking for risk factors influencing this fact. They hypothesize that it may be because of microbiota dysbiosis. Microbiota dysbiosis has been known to promote cancer development through immunity dysregulation and chronic inflammation. Microbiomes profile in late-onset colorectal cancer (LOCRC) among older patients has been documented, but there is still lack of data about microbial profiles among younger colorectal cancer (CRC) patients. This review tries to explain microbial profiles differences between EOCRC and LOCRC as a potential diagnostic biomarker in the future, and whether microbiota can have a role in EOCRC genesis. Key Messages: Microbiota does vary with age, and EOCRC may be associated with colonization of some specific bacteria. Further studies about gut microbiota profiles in EOCRC and LOCRC may provide a new insight on diagnostic biomarker of CRC. © 2021 S. Karger AG, Basel. Copyright: All rights reserved.	Colorectal cancer; Diagnostic biomarker; Early-onset colorectal cancer; Gut microbiota; Microbiota dysbiosis	biological marker; colorectal tumor; dysbiosis; human; incidence; intestine flora; Biomarkers; Colorectal Neoplasms; Dysbiosis; Gastrointestinal Microbiome; Humans; Incidence	S. Karger AG	00122823	34433172	Review	Q2	882	5279	View
5372(1)
No records
810	Suwantika A.A., Zakiyah N., Abdulah R., Sitohang V., Tandy G., Anartati A., Hidayatullah T., Herliana P., Hadinegoro S.R.	55757798100;56073623400;9244834900;57201802658;57208105012;35602938500;35117792500;57203394399;57226218772;	Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia	2021	Journal of Environmental and Public Health	2021		7494965				https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105700019&doi=10.1155%2f2021%2f7494965&partnerID=40&md5=bbd858611fb710b7cc2cabf814a8c66b	Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Department of Child Health, Faculty of Medicine, Universitas Indonesia, Jakarta, 10440, Indonesia	Suwantika, A.A., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Zakiyah, N., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Abdulah, R., Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, 45363, Indonesia, Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, 45363, Indonesia; Sitohang, V., Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Tandy, G., Directorate of Health Surveillance and Quarantine, Directorate General of Disease Prevention and Control, Ministry of Health, Jakarta, 12750, Indonesia; Anartati, A., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Hidayatullah, T., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Herliana, P., Clinton Health Access Initiative, Jakarta, 10450, Indonesia; Hadinegoro, S.R., Department of Child Health, Faculty of Medicine, Universitas Indonesia, Jakarta, 10440, Indonesia	As a country with the high number of deaths due to pneumococcal disease, Indonesia has not yet included pneumococcal vaccination into the routine program. This study aimed to analyse the cost-effectiveness and the budget impact of pneumococcal vaccination in Indonesia by developing an age-structured cohort model. In a comparison with no vaccination, the use of two vaccines (PCV10 and PCV13) within two pricing scenarios (UNICEF and government contract price) was taken into account. To estimate the cost-effectiveness value, a 5-year time horizon was applied by extrapolating the outcome of the individual in the modelled cohort until 5 years of age with a 1-month analytical cycle. To estimate the affordability value, a 6-year period (2019-2024) was applied by considering the government's strategic plan on pneumococcal vaccination. In a comparison with no vaccination, the results showed that vaccination would reduce pneumococcal disease by 1,702,548 and 2,268,411 cases when using PCV10 and PCV13, respectively. Vaccination could potentially reduce the highest treatment cost from the payer perspective at $53.6 million and $71.4 million for PCV10 and PCV13, respectively. Applying the UNICEF price, the incremental cost-effectiveness ratio (ICER) from the healthcare perspective would be $218 and $162 per QALY-gained for PCV10 and PCV13, respectively. Applying the government contract price, the ICER would be $987 and $747 per QALY-gained for PCV10 and PCV13, respectively. The result confirmed that PCV13 was more cost-effective than PCV10 with both prices. In particular, introduction cost per child was estimated to be $0.91 and vaccination cost of PCV13 per child (3 doses) was estimated to be $16.61 and $59.54 with UNICEF and government contract prices, respectively. Implementation of nationwide vaccination would require approximately $73.3-$75.0 million (13-14% of routine immunization budget) and $257.4-$263.5 million (45-50% of routine immunization budget) with UNICEF and government contract prices, respectively. Sensitivity analysis showed that vaccine efficacy, mortality rate, and vaccine price were the most influential parameters affecting the ICER. In conclusion, pneumococcal vaccination would be a highly cost-effective intervention to be implemented in Indonesia. Yet, applying PCV13 with UNICEF price would give the best cost-effectiveness and affordability values on the routine immunization budget. © 2021 Auliya A. Suwantika et al.		pcv 10; Pneumococcus vaccine; Pneumococcus vaccine; Article; budget; budget impact analysis; case control study; case fatality rate; child; cohort analysis; comparative effectiveness; contract; controlled study; cost effectiveness analysis; drug cost; drug efficacy; economic evaluation; government; health care cost; human; incidence; incremental cost effectiveness ratio; Indonesia; infection prevention; mortality rate; outcome assessment; pneumococcal infection; price; quality adjusted life year; sensitivity analysis; strategic planning; Streptococcus pneumonia; United Nations Children's Fund; vaccination; cost benefit analysis; economics; Budgets; Child; Cost-Benefit Analysis; Humans; Indonesia; Pneumococcal Vaccines; Vaccination	Hindawi Limited	16879805	33995536	Article	Q2	869	5372	View

Publikasi Scopus 926 artikel (Per 14 Maret 2022)